Authors
Latest:
Expert: Digital Transformation is Key Part of Biopharma C-Suite Goals for 2024Stephanie L. Woerner, PhD, director and principal research scientist at the MIT Center for Information Systems Research, discusses the outlook for next year among biopharma firms.
Latest:
Unique Challenges to Market Access for Ophthalmology BiosimilarsCatherine Humphries sheds light on three key market access challenges within the ophthalmology biosimilars space.
Latest:
Fail-First Policies Are Harming PatientsPatients should not have to wait to access the medication they need.
Latest:
Reshaped Priorities Pave Cold Chain PathHow recent advancements in practice and technology have ushered in a new era of pharmaceutical logistics.
Latest:
Right product, right place, right awayA prescription for making the pharma supply chain more resilient, reliable and disruption-proof
Latest:
11 Market Access Questions to Address Prior to Launching Your First Specialty DrugWednesday, October 5, 2022, 11am EDT Market access considerations can be complex to navigate and overwhelming to address for biopharmaceutical commercial teams launching their first specialty drug. Get answers to eleven key questions that will help guide commercial teams in effectively launching specialty products.
Latest:
The Consolidated Appropriations Act and PBM TransparencyNew federal law introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients.
Latest:
The Key Steps Ahead of DSCSA D-DayA recommended checklist for manufacturers as they enlist distributor and 3PL support—and the important questions they should be asking themselves
Latest:
The Burgeoning Specialty Drug Market: A Case for Guaranteed ValueAn actionable perspective on the future of specialty drug value-based contracting
Latest:
Plan of attack for small company supplier negotiationsHow emerging life sciences organizations can create value with suppliers
Latest:
Preparing for Peak Season with Temperature-controlled ContainersThe pharma logistics peak season—and most of 2022—is going to be challenging for pharmaceutical shippers, forwarders and the air cargo industry. But making slight changes—such as choosing the right packaging—can make it easier.
Latest:
Navigating the Complexities of Prescription Drug Pricing: Affordable Solutions Are Available to Self-Insured Plan SponsorsThe lack of transparency in the pharmaceutical industry further exacerbates the challenges faced by consumers.
Latest:
The CGT Evolution: Key ConsiderationsHow cell and gene therapies can be safely protected as they move along the supply chain, even when temperature-related challenges present themselves.
Latest:
High-Tech Hubs and Specialty PharmaWith the rapid rise of the specialty drug market, manufacturers are increasingly relying on new advances used by patient hubs to boost their levels of patient engagement.
Latest:
In the Shadows of the Drug Affordability Debate, Patients Pay the Ultimate PriceAll healthcare stakeholders must participate to dismantle barriers and ensure access to medicines that save lives.
Latest:
Strengthening the Cold Chain: Insights Gained from COVID-19A breakdown of how the industry is using these lessons to move full steam ahead.
Latest:
CSA a Game Changer for the Life Sciences?Exploring the FDA’s latest proposed guidance on computer system validation, and the movement toward a less burdensome approach
Latest:
An Economic Path Forward: Thoughts on an Industry Inflection PointThe life sciences industry is at an inflection point, with pressures around pricing, patient access, and affordability converging with the cost of increasingly complex and personalized medicines to make today’s economics unsustainable. Scott Howell and Ray Pressburger discuss what can be done to help solve these challenges across the industry.
Latest:
An Economic Path Forward: Thoughts on an Industry Inflection PointThe life sciences industry is at an inflection point, with pressures around pricing, patient access, and affordability converging with the cost of increasingly complex and personalized medicines to make today’s economics unsustainable. Scott Howell and Ray Pressburger discuss what can be done to help solve these challenges across the industry.
Latest:
Tapping into Digital IntelligenceUsing technology to personalize customer engagement, build HCP trust.
Latest:
The Do’s of Evaluating Cell Sourcing PartnersFactors to keep in mind before obtaining material in the cell therapy space.
Latest:
Benefits of Structured Content in Preparing Data for Regulatory SubmissionsHow taking steps to incorporate data into all regulatory and labeling operations helps firms avoid retroactively planning to recapture information
Latest:
The Evolving Value Assessment Landscape in the USHow current frameworks influence coverage decisions and pricing negotiations.
Latest:
DSCSA 2024 or 2023 Déjà Vu?A look at the challenges that need to be addressed during the FDA stabilization period.
Latest:
Challenges in Cell and Gene Therapy Manufacturing, Sterility AssuranceManufacturers should leverage the knowledge base of personnel working in sterility assurance and in microbiology laboratories.
